Surgeon Perspective: Module

CE / CME

Immune Checkpoint Inhibitor–Based Therapy for Early-Stage Lung Cancer: Surgeon Perspective

Pharmacists: 0.75 contact hour (0.075 CEUs)

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Nurses: 0.75 Nursing contact hour

Released: December 01, 2021

Expiration: November 30, 2022

Jonathan Spicer
Jonathan Spicer, MD, PhD, FRCS

Activity

Progress
1
Course Completed

References

  1. Asamura H, Okada M, Saji H, et al. Randomized trial of segmentectomy compared to lobectomy in small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Presented at: 101st Annual Meeting of the American Association of Thoracic Surgery. April 30-May 2, 2021.
  2. Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711-1723.
  3. Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (Impower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398:1344-1357.
  4. Albain KS, Swann RS, Rusch VW, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet. 2009;374:379-386.
  5. Hui Z, Men Y, Hu C, et al. Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small-cell lung cancer after complete resection and adjuvant chemotherapy: the phase32 PORT-C randomized clinical trial. JAMA Oncol. 2021;7:1178.
  6. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
  7. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
  8. Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst. 1994;86:673-680.
  9. Rosell R, Gómez-Codina J, Camps, C, et al. A randomized trial comparing perioperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med. 1994;330:153-158.
  10. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39-51.
  11. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976.
  12. Huynh C, Walsh LA, Spicer JD. Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer. Transl Lung Cancer Res. 2021;10:563-580.
  13. Hellmann MD, Chaft JE, William WB Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol. 2014;15:e42-50.
  14. Ferreira V, Minnella EM, Awasthi R, et al. Multimodal prehabilitation for lung cancer surgery: a randomized controlled trial. Ann Thorac Surg. 2021;112:1600-1608.
  15. Schmid S, Minnella EM, Najmeh S, et al. Neoadjuvant prehabilitation therapy for locally advanced non-small-cell lung cancer: optimizing outcomes through the trajectory of care. Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting; June 4-8, 2021. Abstract e20545.
  16. Brandt WS, Yan W, Zhou J, et al. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: a propensity-matched analysis. J Thorac Cardiovasc Surg. 2019;157:743-753.
  17. ClinicalTrials.gov. A study of atezolizumab as neoadjuvant and adjuvant therapy in resectable non-small cell lung cancer (NSCLC) – Lung cancer mutation consortium (LCMC3). clinicaltrials.gov/ct2/show/NCT02927301. Accessed November 16, 2021.
  18. Lee JM, Chaft J, Nicholas A, et al: Surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis. Presented at: 22nd World Conference On Lung Cancer of the International Association for the Study of Lung Cancer; January 28-31, 2021. Abstract PS02.05.
  19. Shu CA, Gainor JF, Awad MM, et al. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:786-795.
  20. Provencio M, Nadal E, Insa A, et al. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol. 2020;21:1413-1422.
  21. Forde PM, Spicer J, Lu S, et al. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 checkmate 816 trial. Presented at: American Association for Cancer Research Annual Meeting 2021; April 10-15, 2021. Abstract CT003.
  22. Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 checkMate 816 trial: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting; June 4-8, 2021. Abstract 8503.
  23. ClinicalTrials.gov. A neoadjuvant study of nivolumab plus ipilimumab or nivolumab plus chemotherapy versus chemotherapy alone in early stage non-small cell lung cancer (NSCLC) (checkmate 816). clinicaltrials.gov/ct2/show/NCT02998528. Accessed November 16, 2021.
  24. Lim EK, Batchelor TJ, Dunning J, et al. Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: one-year results from a randomized controlled trial (VIOLET). Presented at: 57th Annual Meeting of the American Society of Clinical Oncology Meeting. June 4-8, 2021. Abstract 8504.
  25. Yoshino I, Yokoyama H, Yano T. Comparison of surgical results of lobectomy with bronchoplasty and pneumonectomy for lung cancer. J Surg Oncol. 1997;64:32-35.
  26. Frick AE, Lüders H, Leschber G. Thirty and 90-day mortality after lung cancer resection in 2242 patients. Presented at: 2015 European Lung Cancer Conference. April 15-18, 2015. Abstract 620.
  27. Blumenthal GM, Bunn PA Jr, Chaft JE, et al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol. 2018;13:1818-1831.
  28. ClinicalTrials.gov. LCRF LEADER neoadjuvant screening trial: LCMC4 evaluation of actionable drivers in early stage lung cancers. https://www.clinicaltrials.gov/ct2/show/NCT04712877. Accessed November 16, 2021.
  29. Osimertinib prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals; 2021.
  30. Atezolizumab prescribing information. South San Francisco, CA: Genentech; 2021.
  31. Alectinib prescribing information. South San Francisco, CA: Genentech; 2021.
  32. ClinicalTrials.gov. Pembrolizumab as neoadjuvant therapy for resectable stage IA3 to IIA non-small cell lung cancer (NSCLC). clinicaltrials.gov/ct2/show/NCT04638582. Accessed November 16, 2021.